What does Evrysdi cost, and what price do people usually pay?
Evrysdi (risdiplam) pricing depends on the market, the dose for the patient’s weight, and whether coverage applies. The price commonly varies by country and payer (commercial insurance, public programs, or out-of-pocket price). The provided information does not include any specific Evrysdi list price or U.S. cash price, so a precise number can’t be stated here.
Is there a difference between U.S. list price and what patients pay?
Yes. The “list price” (the manufacturer’s posted price) can differ a lot from the amount a patient pays after insurance negotiations, copay assistance, or government coverage. Without the available pricing figures for Evrysdi in your country and year, I can’t calculate or quote an expected out-of-pocket cost.
Are there discounts, copay assistance, or patient support programs?
Many specialty drugs like Evrysdi may have manufacturer support and/or reimbursement support, but the provided information does not include the details for Evrysdi programs, eligibility, or copay caps.
How is Evrysdi priced relative to dosing (weight-based) and duration of therapy?
Evrysdi is dosed based on patient factors (including weight), and therapy is typically ongoing. That means the total monthly cost can change with dose and patient category. Without the specific per-milligram price and dosing tables, any monthly estimate would be speculative.
What do you need to get the exact price you can use?
If you tell me:
- your country (e.g., U.S., UK, Canada, EU country),
- whether you want list price or expected out-of-pocket cost,
- and (if relevant) the patient’s age/weight or the prescription format,
I can narrow down what “Evrysdi price” most likely refers to (and whether coverage changes the number).